Sonova AG is a Swiss medical technology company headquartered in Stäfa, Switzerland, founded in 1947. It develops and delivers hearing care solutions across four business segments: Hearing Instruments, Audiological Care, Consumer Hearing, and Cochlear Implants. In its 2024/25 financial year, the company reported CHF 3.9 billion in sales and CHF 547 million in net profit, employing more than 18,000 people worldwide.
The company operates a portfolio of brands serving different parts of the hearing care market. These include Phonak and Unitron for hearing aids, Advanced Bionics for cochlear implants, AudioNova for audiological care services, and the Sennheiser brand for consumer hearing products, held under licence. Its products and services reach customers in over 100 countries. Sonova holds more than 1,800 patents and design rights, reflecting a sustained investment in research and development across hearing aid technology, cochlear implant systems, and wireless audio communication.
The technical domains Sonova works across include:
- Hearing aid design and engineering
- Cochlear implant technology
- Wireless communication systems for hearing applications
- Audiological care services
- Medical device development
Sonova is listed on the SIX Swiss Exchange. Its stated focus is on addressing hearing loss, which the company notes affects more than 1.5 billion people globally, through a combination of clinical-grade devices, consumer products, and direct care services.
